JSKN003 targets HER2 on tumour cells and releases topoisomerase I inhibitors to produce anti-tumour effects ... Phase III or ...

Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Market OverviewThe Global Breast Cancer Therapeutics Market  remains one of the most prevalent forms of cancer worldwide, ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

In this video, Aruna Padmanabhan, MD, discusses the evaluation of PI3K inhibitor combinations as first-line treatment for patients with metastatic breast cancer.

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

Puma Biotechnology will issue its 4Q and full year 2024 results on Feb. 27 and follow with a conference call at 1:30 p.m.

JSKN003 is an anti-HER2 biparatopic ADC, which is developed inhouse with Alphamab's proprietary Glycan-specific conjugation platform. Compared with its ADC counterparts, JSKN003 demonstrated better ...

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.